The Efficacy and Safety Study in Patients With Type 2 Diabetes Mellitus

Inclusion Criteria: * Provision of informed consent prior to any study specific procedures Diagnosed with type 2 diabetes * Men or women who are \>18 years of age at time of consenting upon Visit 1 * HbA1c \>7.5% and ≤11.0% Patients should be drug naive or treated with metformin alone on stable doses of for at least continues 8 weeks prior to Visit 1 * Drug naive patients are defined as patients who have not received medical treatment for diabetes (insulin and/or oral hypo) Exclusion Criteria: * Pregnant or breastfeeding patients * Insulin therapy within one year of enrolment (with the exception of insulin therapy during a hospitalization or use in gestational diabetes) * Previous treatment with any DPP-IV inhibitors or GLP-1 analogue * History of administration of any antihyperglycemic therapy (other than metformin) during the 8 weeks prior to Visit 1(12 weeks for previous TZD) * Treatment with systemic glucocorticoids other than replacement therapy * Inhaled, local injected and topical use of glucocorticoids is allowed